BioTuesdays

Tag - Ladenburg Thalmann

Catabasis Pharma
Markets

Ladenburg starts Catabasis Pharma at buy; PT $6

Ladenburg Thalmann launched coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and price target of $8. The stock closed at $1.78 on May 11. Catabasis is a Boston-based biotechnology company focused...

May 12, 2021
Evaxion-Al-Immunology
Markets

Ladenburg starts Evaxion Biotech at buy; PT $23

Ladenburg Thalmann initiated coverage of Evaxion Biotech A/S (NASDAQ:EVAX) with a “buy” rating and $23 price target. The stock closed at $7.08 on March 1. Evaxion is a clinical-stage artificial intelligence (AI)...

March 2, 2021
Artelo Biosciences Logo
Markets

Ladenburg starts Artelo Biosciences at buy; PT $7

Ladenburg Thalmann initiated coverage of Artelo Biosciences (NASDAQ:ARTL) with a “buy” rating and price target of $7. The stock closed at $1.63 on Feb. 11. Artelo is developing first-in-class, proprietary therapeutics...

February 12, 2021
Viridian
Markets

Ladenburg starts Viridian Therapeutics at buy; PT $40

Ladenburg Thalmann launched coverage of Viridian Therapeutics (NASDAQ:VRDN) with a “buy” rating and $40 price target. The stock closed at $21.78 on Jan. 22. Viridian’s lead asset, VRDN-001, is an anti-IGF-1R monoclonal...

January 25, 2021
Plus Therapeutics Logo
Markets

Ladenburg starts Plus Therapeutics at buy; PT $8

Ladenburg Thalmann initiated coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and price target of $8. The stock closed at $2.43 on Jan. 22. The company’s lead product, rhenium nanoliposome (RNL), is a...

January 25, 2021
Markets

Ladenburg starts Tarsus Pharma at buy; PT $42

Ladenburg Thalmann initiated coverage of Tarsus Pharmaceuticals (NASDAQ:TARS) with a “buy” rating and $42 price target. The stock closed at $23.19 on Nov. 19. Tarsus focuses on the development of novel treatments for...

November 10, 2020
Immunome-Logo
Markets

Ladenburg starts Immunome at buy; PT $28

Ladenburg Thalmann initiated coverage of Immunome (NASDAQ:IMNM) with a “buy” rating and price target of $28. The stock closed at $11.74 on Oct. 23. Immunome is using its Immunome Discovery Engine (IDE) platform to...

October 26, 2020
Cogent Biosciences Logo
Markets

Ladenburg starts Cogent Biosciences at buy; PT $4

Ladenburg Thalmann launched coverage of Cogent Biosciences (NASDAQ:COGT) with a “buy” rating and $4 price target. The stock closed at $2.89 on Oct. 13. Cogent has a late-stage clinical asset, CGT9486, in development for...

October 14, 2020
Avadel Logo
Markets

Ladenburg ups Avadel Pharma PT to $20 from $14

Ladenburg Thalmann raised its price target for Avadel Pharmaceuticals (NASDAQ:AVDL) to $20 from $14 after the company posted positive topline Phase 3 results for FT218, a once nightly formulation of Micropump controlled...

April 28, 2020
Salarius Pharmaceuticals
Markets

Ladenburg starts Salarius Pharma at buy; PT $3.80

Ladenburg Thalmann launched coverage of Salarius Pharmaceuticals (NASDAQ:SLRX) with a “buy” rating and price target of $3.80. The stock closed at 63 cents on April 24. Salarius obtained a NASDAQ listing through a...

April 27, 2020